As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.
BTG’s string-of-beads tempts Boston Scientific to shell out £3.3bn ($4.2bn) for the UK company.
Sequencing data is all well and good, but what does it mean?
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.